NCT04478279
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors treatment 1 / 2 active_not_recruiting NCT03311542
Expanded Access for Pembrolizumab (MK-3475) Not Available Not Available no_longer_available NCT02574533
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma treatment 1 completed NCT04284774
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial treatment 2 active_not_recruiting NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) screening 2 active_not_recruiting NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV treatment 1 active_not_recruiting NCT05786924
A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers No drug interventions treatment 1 active_not_recruiting NCT01898403
Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma diagnostic Not Available completed NCT00006003
SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated treatment 2 terminated NCT01037790
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer treatment 2 completed NCT00036764
BMS-247550 in Treating Patients With Stage IV Melanoma treatment 2 completed NCT01835184
Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery treatment 1 terminated NCT00438984
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma treatment 1 completed NCT00060333
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma No drug interventions treatment 2 completed NCT01638533
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction treatment 1 active_not_recruiting NCT00866177
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT01748747
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery treatment 0 completed NCT00003647
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma treatment 3 completed NCT02263898
Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations treatment 2 withdrawn NCT01703507
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma treatment 1 completed NCT01359956
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma treatment 3 completed NCT00030615
Decitabine in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT01961115
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma treatment 2 completed NCT02298959
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer treatment 1 active_not_recruiting NCT01120275
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma treatment 2 terminated NCT00217542
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery treatment 1 completed NCT00085306
Interferon Beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma treatment 2 completed NCT00553306
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma treatment 1 / 2 completed NCT01307618
Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma treatment 2 terminated NCT00669019
Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT01708941
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery treatment 2 active_not_recruiting NCT01131234
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT01196416
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma treatment 1 / 2 completed NCT00019396
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer treatment 2 completed NCT02304458
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas treatment 1 / 2 completed NCT01328535
Individualized Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT01709435
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors treatment 1 completed NCT00072163
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma treatment 2 completed NCT00121225
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma treatment 2 completed NCT00060125
Tipifarnib in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT00019448
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma treatment 2 completed NCT00281957
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00651157
Viral Therapy in Treating Patients With Metastatic Melanoma treatment 2 completed NCT01522820
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors treatment 1 completed NCT00019682
Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma treatment 3 completed NCT00087373
Vaccine Therapy in Treating Patients With Metastatic Melanoma No drug interventions treatment 2 terminated NCT01519427
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib treatment 2 terminated NCT01970527
Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma treatment 2 terminated NCT00255762
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT00089362
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors treatment 1 completed NCT02013492
Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery treatment 0 completed NCT02203604
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery treatment 2 terminated NCT01989572
Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery prevention 3 completed NCT02094872
Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic treatment 2 completed NCT00003646
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT02224781
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma treatment 3 active_not_recruiting NCT00003895
Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma No drug interventions treatment 2 completed NCT01134614
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 active_not_recruiting NCT02107755
Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma treatment 2 completed NCT01258855
Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT02166255
APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery No drug interventions treatment 1 completed NCT00655655
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT01274338
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery treatment 3 active_not_recruiting NCT00006243
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma treatment Not Available completed NCT00026143
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT00019890
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma treatment 2 completed NCT00026221
Bevacizumab With or Without Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT00387751
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma treatment 2 completed NCT00436605
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma treatment 2 completed NCT00243061
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma treatment 2 completed NCT00024011
PS-341 in Treating Patients With Metastatic Malignant Melanoma treatment 2 completed NCT01217411
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer treatment 1 terminated NCT01744171
Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma No drug interventions treatment 1 terminated NCT03220009
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma treatment 2 withdrawn NCT01701037
Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery other 2 terminated NCT00937937
Dinaciclib in Treating Patients With Stage IV Melanoma treatment 2 active_not_recruiting NCT00003552
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma treatment 1 / 2 terminated NCT01989559
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery prevention 1 completed NCT00101270
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas treatment 1 completed NCT00470470
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT00349206
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma treatment 1 completed NCT00005949
Vaccine Plus Interleukin-2 in Treating Patients With Advanced Melanoma treatment 2 completed NCT00303836
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma treatment 2 terminated NCT00861913
Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery treatment 2 completed NCT00110019
Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 3 completed NCT01303341
Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma treatment 1 active_not_recruiting NCT00288041
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma treatment 2 completed NCT02965716
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma treatment 2 active_not_recruiting NCT01103635
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma treatment 1 completed NCT01886235
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery diagnostic Not Available completed NCT01339663
Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma treatment 1 completed NCT00087386
Tanespimycin in Treating Patients With Stage III-IV Melanoma treatment 2 terminated NCT02120222
Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery treatment 1 completed NCT01769222
Ipilimumab and Local Radiation for Selected Solid Tumors treatment 1 terminated NCT01533948
Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery treatment 2 terminated NCT01166126
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV treatment 2 terminated NCT00397982
Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma treatment 2 completed NCT00112476
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors treatment 1 completed NCT02507076
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma treatment Not Available withdrawn NCT00039091
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer treatment 1 terminated NCT00072189
A Phase II Study of UCN-01 in Metastatic Melanoma treatment 2 terminated NCT00085189
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma treatment 2 completed NCT00003789
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg treatment 3 completed NCT01316692
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma No drug interventions treatment 2 terminated NCT05717140
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung treatment 1 not_yet_recruiting NCT00945269
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma treatment 1 / 2 terminated NCT02236546
FDG-PET in Advanced Melanoma No drug interventions diagnostic Not Available terminated NCT02296112
Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations treatment 2 completed NCT02145910
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases treatment 1 withdrawn NCT00871481
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma treatment 1 / 2 completed NCT00450255
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT00074308
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers treatment 1 / 2 completed NCT01851408
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma treatment 2 withdrawn